Journal Mobile Options
Table of Contents
Vol. 71, No. 6, 2002
Issue release date: November–December 2002
Psychother Psychosom 2002;71:318–325
(DOI:10.1159/000065990)

Predictors of Course and Outcome in Hypochondriasis after Cognitive-Behavioral Treatment

Hiller W. · Leibbrand R. · Rief W. · Fichter M.M.
aRoseneck Center of Behavioral Medicine, Prien, bPsychological Institute, University of Mainz, cPsychological Institute, University of Marburg, dDepartment of Psychiatry, University of Munich, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Predictors of treatment outcome were evaluated in a clinical sample suffering from hypochondriasis. Methods: The sample consisted of 96 patients with hypochondriacal disorder according to DSM-IV or high syndrome scores on the Illness Attitude Scales (IAS) or Whiteley Index (WI). After intense inpatient cognitive-behavioral treatment (CBT), 60% of the patients were classified as responders because of substantial improvements or recovery from hypochondriacal symptomatology. Results: Non-responders were characterized by a higher degree of pre-treatment hypochondriasis, more somatization symptoms and general psychopathology (SCL-90R), more dysfunctional cognitions related to bodily functioning, higher levels of psychosocial impairments, and more utilization of the health care system as indicated by the number of hospital days and costs for inpatient treatments and medication. No predictive value was found for sociodemographic variables, comorbidity with other mental disorders and chronicity. Multiple linear regression showed that pre-treatment variables significantly predicted IAS scores at post-treatment (R2 = 0.59), changes during treatment (0.10), IAS scores at follow-up two years later (0.41) and changes between baseline and follow-up (0.25). Conclusions: The results demonstrate the relevance of various psychopathological variables and health care utilization as important indicators for outcome and further course of clinical hypochondriasis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington DC, American Psychiatric Association, 1994.
  2. Fava GA, Molnar G, Zielezny M: Health attitudes of psychiatric inpatients. Psychopathology 1987;20:180–186.
  3. Noyes R, Kathol RG, Fisher MM, Phillips BM, Suelzer MT, Woodman CL: Psychiatric comorbidity among patients with hypochondriasis. Gen Hosp Psychiatry 1994;16:78–87.
  4. Barsky AJ, Wyshak G: Hypochondriasis and somatosensory amplification. Br J Psychiat 1990;157:404–409.
  5. Rief W, Hiller W, Margraf J: Cognitive aspects of hypochondriasis and the somatization syndrome. J Abnorm Psychol 1998;107:587–595.
  6. Rief W, Auer C: Is somatization a habituation disorder? Physiological reactivity in somatization syndrome. Psychiatry Res 2000;101:63–74.

    External Resources

  7. Gureje O, Üstün TB, Simon GE: The syndrome of hypochondriasis: A cross-national study in primary care. Psychol Med 1997;27:1001–1010.
  8. Hiller W, Rief W, Fichter MM: How disabled are patients with somatoform disorders? Gen Hosp Psychiatry 1997;19:432–438.
  9. Fava GA, Sonino N: Psychosomatic medicine: Emerging trends and perspectives. Psychother Psychosom 2000;69:184–197.
  10. Barsky AJ: Amplification, somatization, and the somatoform disorders. Psychosomatics 1992;33:28–34.
  11. Barsky AJ, Cleary PD, Sarnie MK, Klerman GL: The course of transient hypochondriasis. Am J Psychiatry 1993;150:484–488.
  12. Robbins JM, Kirmayer LJ: Transient and persistent hypochondriacal worry in primary care. Psychol Med 1996;26:575–589.
  13. Bouman TK, Visser S: Cognitive and behavioural treatment of hypochondriasis. Psychother Psychosom 1998;67:214–221.
  14. Warwick HMC, Salkovskis PM: Cognitive-behavioral treatment of hypochondriasis; in Starcevic V, Lipsitt DR (eds): Hypochondriasis: Modern Perspectives on an Ancient Malady. New York, Oxford University Press, 2001, pp 314–328.
  15. Warwick HMC, Clark DM, Cobb AM, Salkovskis PM: A controlled trial of cognitive-behavioural treatment of hypochondriasis. Br J Psychiatry 1996;169:189–195.
  16. Clark DM, Salkovskis PM, Hackmann A, Wells A, Fennell M, Ludgate J, Ahmad S, Richards HC, Gelder M: Two psychological treatments for hypchondriasis. Br J Psychiatry 1998;173:218–225.
  17. Visser S, Bouman TK: The treatment of hypochondriasis: exposure plus response prevention vs cognitive therapy. Behav Res Ther 2001;39:423–442.
  18. Kroenke K, Swindle R: Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom 2000;69:201–215.

    External Resources

  19. Rief W, Hiller W, Geissner E, Fichter MM: A two-year follow-up study of patients with somatoform disorders. Psychosomatics 1995;36:376–386.
  20. Speckens AEM, van Hemert AM, Spinhoven P, Hawton KE, Bolk JH, Rooijmans HGM: Cognitive behavioural therapy for medically unexplained physical symptoms: A randomized controlled trial. BMJ 1995;311:1328–1332.
  21. Speckens AEM, van Hemert AM, Spinhoven P, Bolk JH: The diagnostic and prognostic significance of the Whitely Index, the Illness Attitude Scales and the Somatosensory Amplification Scale. Psychol Med 1996;26:1085–1090.
  22. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-II). Washington DC, American Psychiatric Press, 1997.
  23. Hiller W, Zaudig M, Mombour W: Development of diagnostic checklists for use in routine clinical care. Arch Gen Psychiatry 1990;47:782–784.
  24. Hiller W, Zaudig M, Mombour W: IDCL. International Diagnostic Checklists for ICD-10 and DSM-IV. Seattle, Hogrefe & Huber Publishers, 1996.
  25. Kellner R: Manual of the IAS (Illness Attitude Scales). Albuquerque, University of New Mexico, 1981.
  26. Kellner R: Illness Attitude Scales; in Kellner R (ed): Somatization and Hypochondriasis. New York, Praeger-Greenwood Publishers, 1986, pp 319–324.
  27. Fava GA, Grandi S: Differential diagnosis of hypochondriacal fears and beliefs. Psychother Psychosom 1991;55:114–119.
  28. Hiller W, Rief W, Fichter MM: Dimensional and categorical approaches to hypochondriasis. Psychol Med, in press.
  29. Pilowsky I: Dimensions of hypochondriasis. Br J Psychiatry 1967;113:89–93.
  30. Kellner R: Prognosis of treated hypochondriasis. Acta Psych Scand 1983;67:69–79.
  31. Fava GA, Grandi S, Rafanelli C, Fabbri S, Cazzaro M: Explanatory therapy in hypochondriasis. J Clin Psychiatry 2000;61:317–322.
  32. Rief W, Hiller W: Somatisierungsstörung und Hypochondrie [Somatization disorder and hypochondriasis: a treatment manual]. Göttingen, Hogrefe Publishers, 1998.
  33. Rief W, Hiller W, Heuser J: SOMS – Screening für Somatoforme Störungen. Manual zum Fragebogen [SOMS – The screening for somatoform symptoms – Manual]. Bern, Huber Publishers, 1997.
  34. Beck AT, Steer RA, Garbin MG: Psychometric properties of the Beck depression inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:77–100.

    External Resources

  35. Derogatis LR: The SCL-90-R Manual: Scoring administration procedures for the SCL-90-R. Baltimore, Johns Hopkins University School of Medicine, Clinical Psychometrics Unit, 1983.
  36. Barsky AJ, Wyshak G, Klerman GL: The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatry Res 1990;24:323–334.
  37. Chadda RK, Bhatia MS, Shome S, Thakur KN: Psychosocial dysfunction in somatising patients. Br J Psychiatry 1993;163:510–513.
  38. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, Oliveri ME: Patient predictors of response to psychotherapy and pharmacotherapy: Findings in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1991;148:997–1008.
  39. Noyes RJ, Kathol R, Fisher M, Phillips B, Suelzer M, Woodman C: One year follow up of medical outpatients with hypochondriasis. Psychosomatics 1994;35:533–545.
  40. Barsky AJ, Fama JM, Bailey ED, Ahern DK: A prospective 4–5 year study of DSM-III-R hypochondriasis. Arch Gen Psychiatry 1998;55:737–744.
  41. Barsky AJ, Bailey ED, Fama JM, Ahern DK: Predictors of remission in DSM hypochondriasis. Compr Psychiatry 2000;41:179–183.
  42. Simon GE, Gureje O, Fullerton C: Course of hypochondriasis in an international primary care study. Gen Hosp Psychiatry 2001;23:51–55.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50